Sarepta Therapeutics
(NASDAQ) SRPT
Sarepta Therapeutics Financials at a Glance
Market Cap
$1.75B
Revenue (TTM)
$2.20B
Net Income (TTM)
$713.41M
EPS (TTM)
$-8.44
P/E Ratio
-1.98
Dividend
$0.00
Beta (Volatility)
1.02 (Average)
Dividend
$0.00
Beta (Volatility)
1.02 (Average)
Price
$16.67
Volume
2,864,089.873
Open
$16.68
Price
$16.67
Volume
2,864,089.873
Open
$16.68
Previous Close
$16.69
Daily Range
$16.53 - $17.33
52-Week Range
$10.41 - $76.67
Dividend
$0.00
Beta (Volatility)
1.02 (Average)
Price
$16.67
Volume
2,864,089.873
Open
$16.68
Previous Close
$16.69
Daily Range
$16.53 - $17.33
52-Week Range
$10.41 - $76.67
SRPT News
SRPT: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Sarepta Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
835
CEO
Douglas S. Ingram
Website
www.sarepta.comHeadquarters
Cambridge, MA 02142, US
SRPT Financials
Key Financial Metrics (TTM)
Gross Margin
62%
Operating Margin
-32%
Net Income Margin
-32%
Return on Equity
-63%
Return on Capital
-31%
Return on Assets
-21%
Earnings Yield
-50.51%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$1.75B
Shares Outstanding
104.99M
Volume
2.86M
Short Interest
0.00%
Avg. Volume
2.61M
Financials (TTM)
Gross Profit
$1.32B
Operating Income
$657.77M
EBITDA
$647.97M
Operating Cash Flow
$205.48M
Capital Expenditure
$101.97M
Free Cash Flow
$307.45M
Cash & ST Invst.
$939.65M
Total Debt
$1.04B
Sarepta Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$442.93M
-32.7%
Gross Profit
$44.23M
-91.6%
Gross Margin
9.98%
N/A
Market Cap
$1.75B
N/A
Market Cap/Employee
$1.28M
N/A
Employees
1,372
N/A
Net Income
$282.85M
-277.8%
EBITDA
$252.20M
-235.1%
Quarterly Fundamentals
Net Cash
$99.90M
-952.2%
Accounts Receivable
$398.23M
-38.7%
Inventory
$914.74M
+22.0%
Long Term Debt
$1.03B
-22.7%
Short Term Debt
$11.20M
-16.9%
Return on Assets
-21.30%
N/A
Return on Invested Capital
-31.04%
N/A
Free Cash Flow
$125.38M
+132.3%
Operating Cash Flow
$131.21M
+42.5%